CD68-TAMs as predictors of postsurgical distant organ metachronous metastasis in 110 patients with PDAC, according to adjuvant chemotherapy treatment
| Adjuvant chemotherapy treatment | ||||||
|---|---|---|---|---|---|---|
| No | Yes | |||||
| Metachronous metastasis (%) | HR (95% CI)* | p Value | Metachronous metastasis (%) | HR (95% CI)* | p Value | |
| CD68-TAM (%IRA)† (quartiles) | ||||||
| First | 3/12 (25) | 1.00 ref. | 7/16 (44) | 1.00 ref. | ||
| Second | 2/7 (29) | 1.22 (0.20 to 7.34) | 0.83 | 10/20 (50) | 1.01 (0.39 to 2.67) | 0.97 |
| Third | 4/9 (44) | 2.94 (0.62 to 13.94) | 0.17 | 11/18 (61) | 1.05 (0.40 to 2.73) | 0.92 |
| Fourth | 6/8 (75) | 5.10 (1.18 to 22.11) | 0.02 | 11/20 (55) | 0.76 (0.29 to 1.99) | 0.58 |
*Cox regression analysis.
†Densities as percentage immunoreactive area (IRA) at the tumour invasive front.
%IRA, percentage immunoreactive area; PDAC, pancreatic ductal adenocarcinoma; TAMs, tumour-associated macrophages.